Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for JAMES A. COOKE
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 38.49 - 75.17
Open     -
Vol / Avg. 0.00/1.06M
Mkt cap 9.12B
P/E     -
Div/yield     -
EPS -0.25
Shares 148.48M
Beta 1.07
Inst. own 98%
May 27, 2015
Alkermes Plc Annual Shareholders Meeting - 7:00AM EDT - Add to calendar
May 18, 2015
Alkermes Plc at UBS Global Healthcare Conference
Apr 30, 2015
Q1 2015 Alkermes Plc Earnings Release
Apr 30, 2015
Q1 2015 Alkermes Plc Earnings Call - Webcast
Mar 10, 2015
Alkermes Plc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Alkermes Plc at Cowen Health Care Conference
Mar 2, 2015
Alkermes Plc Investor Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -19.02% -4.86%
Operating margin -16.94% -14.08%
EBITD margin - 1.77%
Return on average assets -6.39% -1.72%
Return on average equity -8.73% -2.44%
Employees 1,300 -
CDP Score - -


Connaught House 1 Burlington Road, Dublin 4
DUBLIN, 00000
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alkermes PLC, is an Ireland-based biopharmaceutical company. The Company is positioned to be an engine of treatments for clinical conditions specifically focused on central nervous system disorders, such as schizophrenia, addiction and depression. The products are based on science and technology that provide treatment options for patients with chronic diseases. The Company’s productline includes: Risperdal Consta, a long-acting injectable medication for treatment of Bipolar I Disorder; Invega Sustenna, used for treatment of schizophrenia and schizoaffective disorder; Vivitrol, a prescription injectable medicine used to treat alcohol dependence and prevent relapse to opioid dependence after opioid detox; Bydureon, injectable prescription to treat type 2 diabetes mellitus; Ampyra, oral medication for treatment of multiple sclerosis; Xeplion, treatment of schizophrenia in adult patients, and Fampyra, for treatment of multiple sclerosis.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 56
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President, Corporate Communications
Age: 38
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters